KEGG   DRUG: Mirikizumab
Entry
D11123                      Drug                                   
Name
Mirikizumab (USAN/INN);
Mirikizumab (genetical recombination) (JAN);
Mirikizumab-mrkz;
Omvoh (TN)
Product
Formula
C6380H9842N1686O2004S48
Exact mass
143676.665
Mol weight
143765.6253
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGSSVKV SCKASGYKFT RYVMHWVRQA PGQGLEWMGY INPYNDGTNY
NEKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNW DTGLWGQGTT VTVSSASTKG
PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEAA GGPSVFLFPP
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV
LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ EEMTKNQVSL
TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC
SVMHEALHNH YTQKSLSLSL G
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKASDHIL KFLTWYQQKP GKAPKLLIYG ATSLETGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQM YWSTPFTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H129-L214, H142-H198, H221-H'221, H224-H'224, H256-H316, H362-H420, H'22-H'96, H'129-L'214, H'142-H'198, H'256-H'316, H'362-H'420, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 2399
ATC code: L04AC24
Product: D11123<JP/US>
Efficacy
Anti-inflammatory, Antipsoriatic, Anti-IL-23 antibody
  Disease
Ulcerative colitis [DS:H01466]
  Type
Monoclonal antibody
Target
IL23A [HSA:51561] [KO:K05426]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC24 Mirikizumab
      D11123  Mirikizumab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  23  Digestive organ agents
   239  Miscellaneous
    2399  Others
     D11123  Mirikizumab (USAN/INN); Mirikizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D11123  Mirikizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D11123  Mirikizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL23A
     D11123  Mirikizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11123
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11123
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11123
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11123
Other DBs
CAS: 1884201-71-1
PubChem: 376219047
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system